The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma

Elisa Oricchio, Gouri Nanjangud, Andrew L. Wolfe, Jonathan H Schatz, Konstantinos J. Mavrakis, Man Jiang, Xiaoping Liu, Joanne Bruno, Adriana Heguy, Adam B. Olshen, Nicholas D. Socci, Julie Teruya-Feldstein, Frances Weis-Garcia, Wayne Tam, Rita Shaknovich, Ari Melnick, Juha P. Himanen, R. S K Chaganti, Hans Guido Wendel

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Insights into cancer genetics can lead to therapeutic opportunities. By cross-referencing chromosomal changes with an unbiased genetic screen we identify the ephrin receptor A7 (EPHA7) as a tumor suppressor in follicular lymphoma (FL). EPHA7 is a target of 6q deletions and inactivated in 72% of FLs. Knockdown of EPHA7 drives lymphoma development in a murine FL model. In analogy to its physiological function in brain development, a soluble splice variant of EPHA7 (EPHA7 TR) interferes with another Eph-receptor and blocks oncogenic signals in lymphoma cells. Consistent with this drug-like activity, administration of the purified EPHA7 TR protein produces antitumor effects against xenografted human lymphomas. Further, by fusing EPHA7 TR to the anti-CD20 antibody (rituximab) we can directly target this tumor suppressor to lymphomas in vivo. Our study attests to the power of combining descriptive tumor genomics with functional screens and reveals EPHA7 TR as tumor suppressor with immediate therapeutic potential.

Original languageEnglish (US)
Pages (from-to)554-564
Number of pages11
JournalCell
Volume147
Issue number3
DOIs
StatePublished - Oct 28 2011
Externally publishedYes

Fingerprint

EphA1 Receptor
Eph Family Receptors
Follicular Lymphoma
Tumors
Lymphoma
Neoplasms
Genomics
Anti-Idiotypic Antibodies
Brain

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Oricchio, E., Nanjangud, G., Wolfe, A. L., Schatz, J. H., Mavrakis, K. J., Jiang, M., ... Wendel, H. G. (2011). The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell, 147(3), 554-564. https://doi.org/10.1016/j.cell.2011.09.035

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. / Oricchio, Elisa; Nanjangud, Gouri; Wolfe, Andrew L.; Schatz, Jonathan H; Mavrakis, Konstantinos J.; Jiang, Man; Liu, Xiaoping; Bruno, Joanne; Heguy, Adriana; Olshen, Adam B.; Socci, Nicholas D.; Teruya-Feldstein, Julie; Weis-Garcia, Frances; Tam, Wayne; Shaknovich, Rita; Melnick, Ari; Himanen, Juha P.; Chaganti, R. S K; Wendel, Hans Guido.

In: Cell, Vol. 147, No. 3, 28.10.2011, p. 554-564.

Research output: Contribution to journalArticle

Oricchio, E, Nanjangud, G, Wolfe, AL, Schatz, JH, Mavrakis, KJ, Jiang, M, Liu, X, Bruno, J, Heguy, A, Olshen, AB, Socci, ND, Teruya-Feldstein, J, Weis-Garcia, F, Tam, W, Shaknovich, R, Melnick, A, Himanen, JP, Chaganti, RSK & Wendel, HG 2011, 'The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma', Cell, vol. 147, no. 3, pp. 554-564. https://doi.org/10.1016/j.cell.2011.09.035
Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell. 2011 Oct 28;147(3):554-564. https://doi.org/10.1016/j.cell.2011.09.035
Oricchio, Elisa ; Nanjangud, Gouri ; Wolfe, Andrew L. ; Schatz, Jonathan H ; Mavrakis, Konstantinos J. ; Jiang, Man ; Liu, Xiaoping ; Bruno, Joanne ; Heguy, Adriana ; Olshen, Adam B. ; Socci, Nicholas D. ; Teruya-Feldstein, Julie ; Weis-Garcia, Frances ; Tam, Wayne ; Shaknovich, Rita ; Melnick, Ari ; Himanen, Juha P. ; Chaganti, R. S K ; Wendel, Hans Guido. / The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. In: Cell. 2011 ; Vol. 147, No. 3. pp. 554-564.
@article{01428f0f0bff405f9b4858b55cee3369,
title = "The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma",
abstract = "Insights into cancer genetics can lead to therapeutic opportunities. By cross-referencing chromosomal changes with an unbiased genetic screen we identify the ephrin receptor A7 (EPHA7) as a tumor suppressor in follicular lymphoma (FL). EPHA7 is a target of 6q deletions and inactivated in 72{\%} of FLs. Knockdown of EPHA7 drives lymphoma development in a murine FL model. In analogy to its physiological function in brain development, a soluble splice variant of EPHA7 (EPHA7 TR) interferes with another Eph-receptor and blocks oncogenic signals in lymphoma cells. Consistent with this drug-like activity, administration of the purified EPHA7 TR protein produces antitumor effects against xenografted human lymphomas. Further, by fusing EPHA7 TR to the anti-CD20 antibody (rituximab) we can directly target this tumor suppressor to lymphomas in vivo. Our study attests to the power of combining descriptive tumor genomics with functional screens and reveals EPHA7 TR as tumor suppressor with immediate therapeutic potential.",
author = "Elisa Oricchio and Gouri Nanjangud and Wolfe, {Andrew L.} and Schatz, {Jonathan H} and Mavrakis, {Konstantinos J.} and Man Jiang and Xiaoping Liu and Joanne Bruno and Adriana Heguy and Olshen, {Adam B.} and Socci, {Nicholas D.} and Julie Teruya-Feldstein and Frances Weis-Garcia and Wayne Tam and Rita Shaknovich and Ari Melnick and Himanen, {Juha P.} and Chaganti, {R. S K} and Wendel, {Hans Guido}",
year = "2011",
month = "10",
day = "28",
doi = "10.1016/j.cell.2011.09.035",
language = "English (US)",
volume = "147",
pages = "554--564",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma

AU - Oricchio, Elisa

AU - Nanjangud, Gouri

AU - Wolfe, Andrew L.

AU - Schatz, Jonathan H

AU - Mavrakis, Konstantinos J.

AU - Jiang, Man

AU - Liu, Xiaoping

AU - Bruno, Joanne

AU - Heguy, Adriana

AU - Olshen, Adam B.

AU - Socci, Nicholas D.

AU - Teruya-Feldstein, Julie

AU - Weis-Garcia, Frances

AU - Tam, Wayne

AU - Shaknovich, Rita

AU - Melnick, Ari

AU - Himanen, Juha P.

AU - Chaganti, R. S K

AU - Wendel, Hans Guido

PY - 2011/10/28

Y1 - 2011/10/28

N2 - Insights into cancer genetics can lead to therapeutic opportunities. By cross-referencing chromosomal changes with an unbiased genetic screen we identify the ephrin receptor A7 (EPHA7) as a tumor suppressor in follicular lymphoma (FL). EPHA7 is a target of 6q deletions and inactivated in 72% of FLs. Knockdown of EPHA7 drives lymphoma development in a murine FL model. In analogy to its physiological function in brain development, a soluble splice variant of EPHA7 (EPHA7 TR) interferes with another Eph-receptor and blocks oncogenic signals in lymphoma cells. Consistent with this drug-like activity, administration of the purified EPHA7 TR protein produces antitumor effects against xenografted human lymphomas. Further, by fusing EPHA7 TR to the anti-CD20 antibody (rituximab) we can directly target this tumor suppressor to lymphomas in vivo. Our study attests to the power of combining descriptive tumor genomics with functional screens and reveals EPHA7 TR as tumor suppressor with immediate therapeutic potential.

AB - Insights into cancer genetics can lead to therapeutic opportunities. By cross-referencing chromosomal changes with an unbiased genetic screen we identify the ephrin receptor A7 (EPHA7) as a tumor suppressor in follicular lymphoma (FL). EPHA7 is a target of 6q deletions and inactivated in 72% of FLs. Knockdown of EPHA7 drives lymphoma development in a murine FL model. In analogy to its physiological function in brain development, a soluble splice variant of EPHA7 (EPHA7 TR) interferes with another Eph-receptor and blocks oncogenic signals in lymphoma cells. Consistent with this drug-like activity, administration of the purified EPHA7 TR protein produces antitumor effects against xenografted human lymphomas. Further, by fusing EPHA7 TR to the anti-CD20 antibody (rituximab) we can directly target this tumor suppressor to lymphomas in vivo. Our study attests to the power of combining descriptive tumor genomics with functional screens and reveals EPHA7 TR as tumor suppressor with immediate therapeutic potential.

UR - http://www.scopus.com/inward/record.url?scp=80155148301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155148301&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2011.09.035

DO - 10.1016/j.cell.2011.09.035

M3 - Article

C2 - 22036564

AN - SCOPUS:80155148301

VL - 147

SP - 554

EP - 564

JO - Cell

JF - Cell

SN - 0092-8674

IS - 3

ER -